Trials / Terminated
TerminatedNCT05309733
A Long-term Follow-up Study of Patients Who Received VOR33
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (actual)
- Sponsor
- Vor Biopharma · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
VOR33 long-term follow-up (LTFU) study
Detailed description
VBP201 study is the VOR33 long-term follow-up (LTFU) study focusing on assessing long term safety and efficacy of VOR33. This study may last up to 15 years (counted from the date of VOR33 infusion completion). All patients who have participated in a study involving the drug product VOR33 and have completed the applicable study or prematurely discontinued, but have at least received the VOR33 infusion, will be asked to participate in the LTFU study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | VOR33 | VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein. |
Timeline
- Start date
- 2022-04-15
- Primary completion
- 2025-05-28
- Completion
- 2025-05-28
- First posted
- 2022-04-04
- Last updated
- 2025-07-29
Locations
11 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05309733. Inclusion in this directory is not an endorsement.